Freshfields represented SERB Pharmaceuticals, a global specialty pharmaceutical company, on its agreement with SFJ Pharmaceuticals, a global drug development company, to acquire exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ. More details about bentracimab and the transaction can be found here. Freshfields served as legal counsel for SERB. The deal team was led by partner Adam Golden, counsel Jeff Jay and Philipp Lehmann, and associate Tanny Kang, alongside partners Paul Humphreys and Madlyn Primoff, counsel Samantha Braunstein and Richard Daniels, senior associates Lacey Nemergut, and Alex Rich, and associates Sora Park, Kelsey Pepper, Anne Powderly, Isabella Shaulis and Jake Silvers. The antitrust team included partner Mary Lehner, special counsel Meytal McCoy and Charles Ramsey, and associate Elizabeth Giordano.